Adoptive t cell immunotherapy restores targeted antiviral immunity in immunodeficient patients

      Background: Adoptive immunotherapy using virus-specific T-lymphocytes (VSTs) has been successful in preventing or treating viral infections after hematopoietic stem cell transplantation (HSCT) with minimal risk of graft versus host disease (GVHD).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect